Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials

BJU International

Volumn 96, Issue 6, 2005, Pages 857-863

  Shabsigh, Ridwan ^a   Burnett, Arthur L ^b   Eardley, Ian ^c   Sharlip, Ira D ^d   Ellsworth, Pamela I ^e   Garcia, Carmen S ^f   Natanegara, Fanni ^f   Ahuja, Sanjeev ^f  

^a Columbia University ^*  (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UMASS MEMORIAL MEDICAL CENTER   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Duration of effectiveness; Erectile function; Phosphodiesterase inhibitors; Sexual Encounter Profile diary; Timing of intercourse attempts

Indexed keywords

SILDENAFIL; TADALAFIL;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERECTILE DYSFUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE;

ADULT; AGED; AGED, 80 AND OVER; CARBOLINES; COITUS; DOUBLE-BLIND METHOD; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; MULTICENTER STUDIES; PHOSPHODIESTERASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME;

EID: 25844511176     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05750.x     Document Type: Article

References (11)

1. Lilly ICOS LLC. Tadalafil Prescribing Information. November, 2003
2. Pfizer Inc. Sildenafil Citrate Prescribing Information. Revised August 2003
3. Bayer Healthcare. Levitra® Vardenafil Hydrochloride Summary of Product Specifications 2003
4. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 121-6
5. Young JM, Feldman RA, Auerbach SM et al. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. J Androl 2005; 26: 310-8
6. Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil in the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332-6
7. Carson CC, Rajfer J, Eardley I et al. The efficacy and safety of tadalafil: an update. BJU Int 2004; 93: 1276-81
8. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
9. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Classer DB, Rimm EB. Sexual function in men older than 50 years of age: results from the Health Professionals Follow-up Study. Ann Intern Med 2003; 139: 161-8
10. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12: 305-11
11. Eardley I, Dean J, Barnes T, Kirby M, Glasser D, Solanki J. The sexual habits of British men and women over 40 years old. BJU Int 2004; 93: 563-7